Changes at week 6 in joint biomarkers, hsCRP and cytokines levels after treatment of hand osteoarthritis patients with placebo or adalimumab
| Adalimumab | Placebo | p Value* | |||
|---|---|---|---|---|---|
| n | ΔMedian (Q1; Q3) | n | ΔMedian (Q1; Q3) | ||
| PIIANP, ng/mL | 36 | 47.6 (−34.6; 167.0) | 31 | 22.5 (−39.1; 119.0) | 0.50 |
| uCTX-II/Creat | 36 | 39.4 (−38.1; 75.2) | 30 | −5.9 (−59.2; 62.6) | 0.61 |
| COMP, UI/L | 36 | −0.0 (−1.4; 0.9) | 31 | 0.1 (−1.0; 1.1) | 0.43 |
| HA, ng/mL | 36 | −0.4 (−13.5; 17.5) | 31 | 5.3 (−13.6; 16.0) | 0.42 |
| hsCRP, mg/dL | 36 | −0.0 (−0.6; 1.0) | 31 | 0.0 (−0.2; 0.3) | 0.58 |
| IL-1, pg/mL | 14 | 0.0 (−0.0; 0.1) | 10 | 0.0 (−0.0; 0.1) | 0.75 |
| IL-6, pg/mL | 36 | −0.1 (−0.4; 0.2) | 31 | −0.0 (−0.2; 0.3) | 0.45 |
| TNF α, pg/mL | 34 | −0.1 (−0.3; 0.1) | 28 | 0.0 (−0.2; 0.2) | 0.13 |
Values are median±IQR.
*Mann–Whitney test.
COMP, cartilage oligomeric matrix protein; HA, hyaluronan, hsCRP, high-sensitivity C reactive protein; IL, interleukin; PIIANP, N-terminal propeptide of type IIA collagen; TNF, tumour necrosis factor.